Trial Profile
A Multicentre, Retrospective, Non‐Interventional Study Investigating the Outcomes of Immune Tolerance Induction with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Patients with Severe Haemophilia A and High‐Titre Inhibitors
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Jan 2019
Price :
$35
*
At a glance
- Drugs Efmoroctocog alfa (Primary)
- Indications Haemophilia A
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bioverativ
- 04 Dec 2018 Interim results (As of July 6, 2018; n=25) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 20 Sep 2018 New trial record